Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Signaling lymphocytic activation molecule family member 5 (SLAMF5, also known as CD84) is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily and a member of the SLAM family of receptors. It is broadly expressed on hematopoietic cells, including T cells, B cells, natural killer cells, dendritic cells, and others. SLAMF5 primarily mediates homophilic (self-ligand) interactions during cell–cell communication, functioning both as an adhesion molecule and as a signaling receptor. It plays a critical role in regulating autophagy and the production of inflammatory cytokines in immune cells, linked to its ITSM-containing cytoplasmic tail which recruits signaling adaptors. Dysregulation of SLAMF5 function has implications in cancer, inflammation, and immune responses to infection[1][2][3][4][7].
Modulation of immune signaling via ITSM (immunoreceptor tyrosine-based switch motif)–dependent recruitment of adaptor proteins (e.g., SAP) Regulation of autophagy and cytokine production, particularly in response to inflammatory stimuli[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Signaling lymphocytic activation molecule family member 5 (SLAMF5).